Medication changes and potentially inappropriate prescribing in older patients with significant polypharmacy
- PMID: 36385206
- DOI: 10.1007/s11096-022-01497-2
Medication changes and potentially inappropriate prescribing in older patients with significant polypharmacy
Abstract
Background: Number of medicines and medicines appropriateness are often used as outcome measures to evaluate the effectiveness of deprescribing interventions.
Aim: The aim of this study was to evaluate changes in prescribing, potentially inappropriate prescriptions (PIP) and prescribing of low-value medicines in older people with multimorbidity and significant polypharmacy.
Method: This study was a retrospective secondary analysis of prescription data from a cluster randomised controlled trial involving 404 participants aged ≥ 65 years and prescribed ≥ 15 repeat medicines from 51 different general practices. For this study, repeat medications at baseline and follow-up (~ 1 year later) were assigned Anatomical Therapeutic Classification (ATC) codes. Outcomes were the most commonly prescribed and potentially inappropriately prescribed drug groups, the most frequently discontinued or initiated drug groups and the number of changes per person between baseline and follow-up.
Results: There were 7051 medicines prescribed to 404 participants at baseline. There was a median of 17 medicines (IQR 15-19) at baseline and 16 (IQR 14-19) at follow-up. PIP represented 17.1% of prescriptions at baseline and 15.7% (n = 6777) at follow-up. There were reductions in the prescription of most drug groups with the largest reduction in antiplatelet prescriptions. Considering medication discontinuations, initiations and switches, there was a median of five medication changes per person (range 0-30, IQR 3-9) by follow-up. There were 95 low-value prescriptions at baseline reducing to 78 at follow-up.
Conclusion: The number of medication changes per person was not reflected by summarising medication count at two time points, highlighting the complexity of prescribing for patients with polypharmacy. Frequent medication changes has potentially important implications for patients in terms of adherence and medication safety.
Trial registry: The SPPiRE trial was registered prospectively on the ISRCTN registry (ISRCTN12752680).
Keywords: Cluster randomised controlled trial; Deprescribing; Multimorbidity; Polypharmacy; Potentially inappropriate prescribing.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Similar articles
-
GP-delivered medication review of polypharmacy, deprescribing, and patient priorities in older people with multimorbidity in Irish primary care (SPPiRE Study): A cluster randomised controlled trial.PLoS Med. 2022 Jan 5;19(1):e1003862. doi: 10.1371/journal.pmed.1003862. eCollection 2022 Jan. PLoS Med. 2022. PMID: 34986166 Free PMC article. Clinical Trial.
-
Supporting prescribing in older people with multimorbidity and significant polypharmacy in primary care (SPPiRE): a cluster randomised controlled trial protocol and pilot.Implement Sci. 2017 Aug 1;12(1):99. doi: 10.1186/s13012-017-0629-1. Implement Sci. 2017. PMID: 28764753 Free PMC article. Clinical Trial.
-
Patient and general practitioner experiences of implementing a medication review intervention in older people with multimorbidity: Process evaluation of the SPPiRE trial.Health Expect. 2022 Dec;25(6):3225-3237. doi: 10.1111/hex.13630. Epub 2022 Oct 17. Health Expect. 2022. PMID: 36245339 Free PMC article. Clinical Trial.
-
Polypharmacy, inappropriate prescribing, and deprescribing in older people: through a sex and gender lens.Lancet Healthy Longev. 2021 May;2(5):e290-e300. doi: 10.1016/S2666-7568(21)00054-4. Lancet Healthy Longev. 2021. PMID: 36098136 Review.
-
Expert-based medication reviews to reduce polypharmacy in older patients in primary care: a northern-Italian cluster-randomised controlled trial.BMC Geriatr. 2021 Nov 23;21(1):659. doi: 10.1186/s12877-021-02612-0. BMC Geriatr. 2021. PMID: 34814835 Free PMC article. Review.
Cited by
-
The effectiveness and cost of integrating pharmacists within general practice to optimize prescribing and health outcomes in primary care patients with polypharmacy: a systematic review.BMC Prim Care. 2023 Feb 6;24(1):41. doi: 10.1186/s12875-022-01952-z. BMC Prim Care. 2023. PMID: 36747132 Free PMC article.
-
Effectiveness of interactive dashboards to optimise prescribing in primary care: a protocol for a systematic review.HRB Open Res. 2025 Feb 19;7:44. doi: 10.12688/hrbopenres.13909.2. eCollection 2024. HRB Open Res. 2025. PMID: 39931386 Free PMC article.
-
Defining, identifying and addressing problematic polypharmacy within multimorbidity in primary care: a scoping review.BMJ Open. 2024 May 24;14(5):e081698. doi: 10.1136/bmjopen-2023-081698. BMJ Open. 2024. PMID: 38803265 Free PMC article.
-
Awareness and use of tools to identify potentially inappropriate prescribing among physicians and pharmacists in Saudi Arabia: a nationwide cross-sectional study.Int J Clin Pharm. 2025 Apr;47(2):435-442. doi: 10.1007/s11096-024-01848-1. Epub 2024 Dec 24. Int J Clin Pharm. 2025. PMID: 39718759
-
Core medication use in general practice prescriptions: A pilot study evaluating the Drug Utilization 90% Index in Irish general practice.Br J Clin Pharmacol. 2025 Apr;91(4):1241-1249. doi: 10.1111/bcp.16356. Epub 2024 Dec 8. Br J Clin Pharmacol. 2025. PMID: 39648621 Free PMC article.
References
-
- Khezrian M, McNeil CJ, Murray AD, et al. An overview of prevalence, determinants and health outcomes of polypharmacy. Therapeut Adv Drug Saf. 2020;11:2042098620933741.
Publication types
MeSH terms
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials